Research

Better data on how cancer patients reach care.

Some of the most important questions in cancer care have little prospective data behind them. HMT's registry is being built to help answer them.

Questions we care about

Where the evidence is thinnest.

Time to specialist care
How long patients wait between a concerning finding and a specialist consultation, and where the delays happen.
Who is missed
Which patients never reach specialist care, and how that differs between academic, community and rural settings.
Rare cancers
Outcomes for cancers with little prospective data, such as appendiceal cancers and low-grade mucinous tumors.
Regional therapies
Where treatments such as cytoreductive surgery with HIPEC fit best, and which patients benefit.

Principles

Privacy first. Identifiers are cleared before a record is admitted to the registry.
Oversight. Studies run under IRB oversight and written data agreements with the institutions involved.
Evidence before claims. We publish what we learn, and we do not describe results until they are validated.

Publications

Publications and presentations will be listed here. If you are an investigator interested in collaborating, we would like to hear from you.